Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker assays designed to improve the detection of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The new biomarker tests will be incorporated into the AVISE® CTD platform, a diagnostic tool widely used to evaluate autoimmune diseases, this month.
The new lupus assay, called the T-Cell Lupus Profile, is designed to help healthcare providers more accurately diagnose lupus and other autoimmune diseases by measuring biomarkers such as TC4d, TIgG, and TIgM, which offer greater sensitivity in identifying lupus, especially in challenging cases.
These advancements aim to provide healthcare professionals with more precise diagnostic tools, enabling faster and more accurate disease identification. The commercial launch of these new tests is planned for January 2025.
The Lupus Foundation of America is proud to have collaborated with Exagen Inc. to support the development of the AVISE® CTD tests. Learn more about using blood tests to diagnose lupus.
This post was originally published on this site